Akt and p53R2, partners that dictate the progression and invasiveness of cancer

DNA Repair

Volumn 22, Issue , 2014, Pages 24-29

  Yousefi, Bahman ^a   Samadi, Nasser ^b   Ahmadi, Yasin ^b,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Akt; Cancer progression; Cell cycle; P53R2; Ribonucleotide reductase

Indexed keywords

CELL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; P53R2 PROTEIN; PARATHION; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; PROTEIN P53; CELL CYCLE PROTEIN; RIBONUCLEOTIDE REDUCTASE; RRM2B PROTEIN, HUMAN;

CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; DNA REPAIR; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; CELL CYCLE CHECKPOINT; CELL CYCLE PROGRESSION; DEPHOSPHORYLATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEAT SHOCK; HYPEROSMOTIC STRESS; OXIDATIVE STRESS; PROTEIN EXPRESSION; ULTRAVIOLET IRRADIATION; ANIMAL; CELL CYCLE; GENETICS; METABOLISM; NEOPLASM;

ANIMALS; CELL CYCLE; CELL CYCLE PROTEINS; DNA REPAIR; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBONUCLEOTIDE REDUCTASES;

EID: 84905283334     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2014.07.001     Document Type: Review

References (84)

1. Bellacosa A., Kumar C.C., Cristofano A.D., Testa J.R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res. 2005, 94:29-86.
2. Yang Z., Tschopp O., Baudry A., Dummler B., Hynx D., Hemmings B. Physiological functions of protein kinase B/Akt. Biochem. Soc. Trans. 2004, 32:350-354.
3. Scheid M.P., Woodgett J.R. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 2003, 546:108-112.
4. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 1998, 10:262-267.
5. Walker E.H., Perisic O., Ried C., Stephens L., Williams R.L. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 1999, 402:313-320.
6. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
7. Kumar V., Zhang M.-X., Swank M.W., Kunz J., Wu G.-Y. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J. Neurosci. 2005, 25:11288-11299.
8. Alessi D.R., Deak M., Casamayor A., Barry Caudwell F., Morrice N., Norman D.G., et al. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr. Biol. 1997, 7:776-789.
9. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.-H., Hsu P.P., Bagley A.F., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168.
10. Zhou J., Schmid T., Frank R., Brüne B. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1α from pVHL-independent degradation. J. Biol. Chem. 2004, 279:13506-13513.
11. Fujio Y., Nguyen T., Wencker D., Kitsis R.N., Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000, 101:660-667.
12. Wan Y., Wang Z., Shao Y., Voorhees J., Fisher G. Ultraviolet irradiation activates PI 3-kinase/AKT survival pathway via EGF receptors in human skin in vivo. Int. J. Oncol. 2001, 18:461-466.
13. Martindale J.L., Holbrook N.J. Cellular response to oxidative stress: signaling for suicide and survival. J. Cell. Physiol. 2002, 192:1-15.
14. Blanco-Aparicio C., Renner O., Leal J.F., Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007, 28:1379-1386.
15. Aman M.J., Lamkin T.D., Okada H., Kurosaki T., Ravichandran K.S. The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells. J. Biol. Chem. 1998, 273:33922-33928.
16. Maira S.-M., Galetic I., Brazil D.P., Kaech S., Ingley E., Thelen M., et al. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 2001, 294:374-380.
17. Millward T.A., Zolnierowicz S., Hemmings B.A. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem. Sci. 1999, 24:186-191.
18. Gao T., Furnari F., Newton A.C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 2005, 18:13-24.
19. Altomare D.A., Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24:7455-7464.
20. Vara J.Á.F., Casado E., de Castro J., Cejas P., Belda-Iniesta C., González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 2004, 30:193-204.
21. Zhang X., Tang N., Hadden T.J., Rishi A.K. Akt, FoxO and regulation of apoptosis. Biochim. Biophys. Acta (BBA) Mol. Cell Res. 2011, 1813:1978-1986.
22. Mitsiades C.S., Mitsiades N., Poulaki V., Schlossman R., Akiyama M., Chauhan D., et al. Activation of NF-kB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002, 21:5673-5683.
23. Ogawara Y., Kishishita S., Obata T., Isazawa Y., Suzuki T., Tanaka K., et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. 2002, 277:21843-21850.
24. Lawlor M.A., Alessi D.R. PKB/Akt a key mediator of cell proliferation, survival and insulin responses?. J. Cell Sci. 2001, 114:2903-2910.
25. Schönherr E., Levkau B., Schaefer L., Kresse H., Walsh K. Decorin-mediated signal transduction in endothelial cells involvement of Akt/protein kinase B in up-regulation of p21WAF1/CIP1 but not p27KIP1. J. Biol. Chem. 2001, 276:40687-40692.
26. Liang J., Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2:339-345.
27. Shiojima I., Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 2002, 90:1243-1250.
28. Ruhul Amin A., Senga T., Oo M.L., Thant A.A., Hamaguchi M. Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, IL-1β: a role for the dual signalling pathways, Akt and Erk. Genes Cells 2003, 8:515-523.
29. Kang S.S., Kwon T., Do S.I. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J. Biol. Chem. 1999, 274:13085-13090.
30. Los M., Maddika S., Erb B., Schulze-Osthoff K. Switching Akt: from survival signaling to deadly response. Bioessays 2009, 31:492-495.
31. Fontecave M., Lepoivre M., Elleingand E., Gerez C., Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 1998, 421:277-279.
32. Yamaguchi T., Matsuda K., Sagiya Y., Iwadate M., Fujino M.A., Nakamura Y., et al. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res. 2001, 61:8256-8262.
33. Wang X., Zhenchuk A., Wiman K.G., Albertioni F. Regulation of p53R2 and its role as potential target for cancer therapy. Cancer Lett. 2009, 276:1-7.
34. Zhou B., Liu X., Mo X., Xue L., Darwish D., Qiu W., et al. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res. 2003, 63:6583-6594.
35. Nakamura Y. Isolation of p53-target genes and their functional analysis. Cancer Sci. 2004, 95:7-11.
36. Xue L., Zhou B., Liu X., Qiu W., Jin Z., Yen Y. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res. 2003, 63:980-986.
37. Zhang K., Wu J., Wu X., Wang X., Wang Y., Zhou N., et al. p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest. Mol. Cancer Ther. 2011, 10:269-278.
38. Pontarin G., Ferraro P., Håkansson P., Thelander L., Reichard P., Bianchi V. p53R2-dependent ribonucleotide reduction provides deoxyribonucleotides in quiescent human fibroblasts in the absence of induced DNA damage. J. Biol. Chem. 2007, 282:16820-16828.
39. Chang L., Zhou B., Hu S., Guo R., Liu X., Jones S.N., et al. ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18519-18524.
40. Thelander L. Ribonucleotide reductase and mitochondrial DNA synthesis. Nat. Genet. 2007, 39:703-704.
41. Polyak K., Li Y., Zhu H., Lengauer C., Willson J.K., Markowitz S.D., et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat. Genet. 1998, 20:291-293.
42. Pontarin G., Ferraro P., Bee L., Reichard P., Bianchi V. Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:13302-13307.
43. Wang X., Liu X., Xue L., Zhang K., Kuo M.-L., Hu S., et al. Ribonucleotide reductase subunit p53R2 regulates mitochondria homeostasis and function in KB and PC-3 cancer cells. Biochem. Biophys. Res. Commun. 2011, 410:102-107.
44. Piao C., Jin M., Kim H., Lee S., Amatya P., Hyun J.-W., et al. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2. Oncogene 2009, 28:2173-2184.
45. Peyssonnaux C., Eychène A. The Raf/MEK/ERK pathway: new concepts of activation. Biol. Cell 2001, 93:53-62.
46. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta (BBA) Mol. Cell Res. 2007, 1773:1263-1284.
47. McCubrey J.A., Steelman L.S., Abrams S.L., Lee J.T., Chang F., Bertrand F.E., et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 2006, 46:249-279.
48. Yousefi B., Rahmati M., Ahmadi Y. The roles of P53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21. Life Sci. 2014.
49. Ohno K., Tanaka-Azuma Y., Yoneda Y., Yamada T. Genotoxicity test system based on p53R2 gene expression in human cells: examination with 80 chemicals. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 2005, 588:47-57.
50. Xue L., Zhou B., Liu X., Heung Y., Chau J., Chu E., et al. Ribonucleotide reductase small subunit p53R2 facilitates p21 induction of G1 arrest under UV irradiation. Cancer Res. 2007, 67:16-21.
51. Garrett M.D. Cell cycle control and cancer. Curr. Sci. 2001, 81:515-522.
52. Li Y., Dowbenko D., Lasky L.A. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J. Biol. Chem. 2002, 277:11352-11361.
53. Koster R., di Pietro A., Timmer-Bosscha H., Gibcus J.H., van den Berg A., Suurmeijer A.J., et al. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J. Clin. Invest. 2010, 120:3594.
54. Carnero A. The PKB/AKT pathway in cancer. Curr. Pharm. Des. 2010, 16:34-44.
55. Marone R., Cmiljanovic V., Giese B., Wymann M.P. Targeting phosphoinositide 3-kinase - moving towards therapy. Biochim. Biophys. Acta (BBA) Proteins Proteomics 2008, 1784:159-185.
56. Alkan S., Izban K.F. Immunohistochemical localization of phosphorylated AKT in multiple myeloma. Blood 2002, 99:2278-2279.
57. Cheong J.W., Eom J.I., Maeng H.Y., Lee S.T., Hahn J.S., Ko Y.W., et al. Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br. J. Haematol. 2003, 122:454-456.
58. Altomare D.A., You H., Xiao G.-H., Ramos-Nino M.E., Skele K.L., De Rienzo A., et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005, 24:6080-6089.
59. Xu Z.-Z., Xia Z.-G., Wang A.-H., Wang W.-F., Liu Z.-Y., Chen L.-Y., et al. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Ann. Hematol. 2013, 92:1351-1358.
60. Muşat M., Korbonits M., Kola B., Borboli N., Hanson M., Nanzer A., et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr. Relat. Cancer 2005, 12:423-433.
61. Miyakawa M., Tsushima T., Murakami H., Wakai K., Isozaki O., Takano K. Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr. J. 2003, 50:77-83.
62. Sartelet H., Rougemont A.-L., Fabre M., Castaing M., Duval M., Fetni R., et al. Activation of the phosphatidylinositol 3'-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1. Hum. Pathol. 2011, 42:1727-1739.
63. Hafner C., Houben R., Baeurle A., Ritter C., Schrama D., Landthaler M., et al. Activation of the PI3K/AKT pathway in Merkel cell carcinoma. PLOS ONE 2012, 7:e31255.
64. Lee S., Kim H., Park W., Kim S., Lee K., Kim S., et al. Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS 2002, 110:587-592.
65. Blackhall F.H., Pintilie M., Michael M., Leighl N., Feld R., Tsao M.-S., et al. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin. Cancer Res. 2003, 9:2241-2247.
66. Pérez-Tenorio G., Stål O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer 2002, 86:540-545.
67. Lim J., Kim J., Paeng J., Kim M., Hong S., Lee J., et al. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J. Clin. Pathol. 2005, 58:1199-1205.
68. Nam S.Y., Lee H.S., Jung G.A., Choi J., Cho S.J., Kim M.K., et al. Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. APMIS 2003, 111:1105-1113.
69. Ghayouri M., Boulware D., Nasir A., Strosberg J., Kvols L., Coppola D. Activation of the serine/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors. Anticancer Res. 2010, 30:5063-5067.
70. Semba S., Moriya T., Kimura W., Yamakawa M. Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas. Pancreas 2003, 26:250-257.
71. Tanno S., Yanagawa N., Habiro A., Koizumi K., Nakano Y., Osanai M., et al. Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance. Cancer Res. 2004, 64:3486-3490.
72. Horiguchi A., Oya M., Uchida A., Marumo K., Murai M. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J. Urol. 2003, 169:710-713.
73. Knowles M.A., Platt F.M., Ross R.L., Hurst C.D. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev. 2009, 28:305-316.
74. Malik S.N., Brattain M., Ghosh P.M., Troyer D.A., Prihoda T., Bedolla R., et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin. Cancer Res. 2002, 8:1168-1171.
75. Faried L.S., Faried A., Kanuma T., Sano T., Nakazato T., Tamura T., et al. Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. Oncol. Rep. 2006, 16:57-64.
76. Kurose K., Zhou X.-P., Araki T., Cannistra S.A., Maher E.R., Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am. J. Pathol. 2001, 158:2097-2106.
77. Link P.A., Baer M.R., James S.R., Jones D.A., Karpf A.R. p53-Inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res. 2008, 68:9358-9366.
78. Okumura H., Natsugoe S., Yokomakura N., Kita Y., Matsumoto M., Uchikado Y., et al. Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin. Cancer Res. 2006, 12:3740-3745.
79. Matsushita S., Ikeda R., Fukushige T., Tajitsu Y., Gunshin K., Okumura H., et al. p53R2 is a prognostic factor of melanoma and regulates proliferation and chemosensitivity of melanoma cells. J. Dermatol. Sci. 2012, 68:19-24.
80. Yanamoto S., Kawasaki G., Yoshitomi I., Mizuno A. Expression of p53R2, newly p53 target in oral normal epithelium, epithelial dysplasia and squamous cell carcinoma. Cancer Lett. 2003, 190:233-243.
81. Uramoto H., Sugio K., Oyama T., Hanagiri T., Yasumoto K. P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer. Anticancer Res. 2006, 26:983-988.
82. Hsu N.-Y., Wu J.-Y., Liu X., Yen Y., Chen C.-Y., Chou M.-C., et al. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer. Anticancer Res. 2011, 31:3475-3481.
83. Devlin H.-L., Mack P.C., Burich R.A., Gumerlock P.H., Kung H.-J., Mudryj M., et al. Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol. Cancer Res. 2008, 6:808-818.
84. Yanamoto S., Iwamoto T., Kawasaki G., Yoshitomi I., Baba N., Mizuno A. Silencing of the p53R2 gene by RNA interference inhibits growth and enhances 5-fluorouracil sensitivity of oral cancer cells. Cancer Lett. 2005, 223:67-76.